← Back to Search

Alkylating agents

Chemotherapy and Stem Cell Transplant for Lung Cancer

Phase 2

Waitlist Available

Research Sponsored by Herbert Irving Comprehensive Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

No untreated or uncontrolled brain metastases

Histologically or cytologically diagnosed lung cancer including relapsed limited stage small cell lung cancer (SCLC), limited stage SCLC responding to conventional radiotherapy, extensive stage SCLC, stage IIIB and IV non-small cell lung cancer (NSCLC), and stages II-IIIA NSCLC who are unable or unwilling to undergo surgery but are acceptable candidates for high dose chemotherapy

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is studying how well giving high-dose combination chemotherapy followed by peripheral stem cell transplantation works in treating patients with lung cancer.

Who is the study for?

This trial is for patients with various stages of lung cancer, including small cell and non-small cell types. Participants must be in good physical condition (Karnofsky score 60-100%), have normal organ function, not be pregnant or breastfeeding, able to consent, and have cryopreserved stem cells ready. There's no age limit.Check my eligibility

What is being tested?

The study is testing the effectiveness of high-dose chemotherapy followed by a peripheral stem cell transplant in lung cancer patients. The goal is to see if this approach can better eliminate cancer cells compared to standard doses.See study design

What are the potential side effects?

High-dose chemotherapy can cause severe fatigue, nausea, hair loss, mouth sores, increased risk of infection due to low blood counts, potential damage to organs like the heart and kidneys, and infertility.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I do not have untreated brain cancer spread.

Select...

My lung cancer diagnosis is confirmed and falls within specific stages.

Select...

My blood, liver, kidney, and lung functions are within normal ranges.

Select...

I can care for myself but may not be able to do active work.

Select...

My stored stem cells have a high enough CD34 count.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

0 / 5Eligibility criteria met

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)NIH

13,662 Previous Clinical Trials

40,925,851 Total Patients Enrolled

Herbert Irving Comprehensive Cancer CenterLead Sponsor

34 Previous Clinical Trials

1,059 Total Patients Enrolled

David G. Savage, MDStudy ChairHerbert Irving Comprehensive Cancer Center

3 Previous Clinical Trials

130 Total Patients Enrolled

Media Library

Combination Chemotherapy (Alkylating agents) Clinical Trial Eligibility Overview. Trial Name: NCT00003284 — Phase 2

Lung Cancer Clinical Trial 2023: Combination Chemotherapy Highlights & Side Effects. Trial Name: NCT00003284 — Phase 2

Combination Chemotherapy (Alkylating agents) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00003284 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment for this clinical study open at the moment?

"According to clinicaltrials.gov, this trial is no longer accepting participants; it was initially listed on January 1st 1998 and last edited on March 1st 2014. Fortunately, there are 1626 other medical studies that are actively recruiting patients at the present moment."

Answered by AI

Has this medication earned the Federal Drug Administration's seal of approval?

"The safety rating for this treatment is a 2, as the trial is currently in Phase 2 with some evidence of security but no data regarding its efficacy."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Lung Cancer

1998. "High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00003284.

All > Stem Cell Transplant > Lung Cancer